DGAP-Adhoc: BB Biotech AG closes the 2019 fiscal year with a profit

2020. január 17., péntek, 07:00





DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Preliminary Results


BB Biotech AG closes the 2019 fiscal year with a profit


17-Jan-2020 / 07:00 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Media Release, January 17, 2020



BB Biotech AG closes the 2019 fiscal year with a profit


In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN CH0038389992) is releasing the following information about its results for its fiscal year 2019.



BB Biotech AG closed its fiscal year 2019 with a profit of approximately CHF 677 million, based on its preliminary unaudited consolidated results (CHF 471 million loss in the previous year).



As an investment company, the results reflect the performance of the stocks BB Biotech AG holds in its investment portfolio.



The publication of all relevant portfolio data will take place on January 17, 2020 at 7:00 am and the complete annual report will be published on February 21, 2020.




For further information:

Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland

Tanja Chicherio, Tel. +41 44 267 67 07, tch@bellevue.ch



www.bbbiotech.com



Company profile



BB Biotech invests in companies in the fast growing market of biotechnology and is one of the world"s largest investors in this sector. BB Biotech is listed in Switzerland, Germany and Italy. Its investments are focused on listed companies that are developing and commercializing novel medical treatments and cures. BB Biotech"s investment selection process is guided by the fundamental research and analysis of physicians and molecular biologists. Its Board of Directors has many years of experience in industry and science.











17-Jan-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: BB BIOTECH AG

Schwertstrasse 6

8200 Schaffhausen

Switzerland
Phone: +41 52 624 08 45
E-mail: info@bbbiotech.com
Internet: www.bbbiotech.ch
ISIN: CH0038389992
WKN: A0NFN3
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX
EQS News ID: 955315





 
End of Announcement DGAP News Service




955315  17-Jan-2020 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=955315&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.